Kaposis Sarcoma

Kaposi's sarcoma, the most common malignancy in patients with HIV infection, occurs in 20-30% of patients (24). The incidence of Kaposi's sarcoma is 300-fold higher in patients with HIV infection compared with those without HIV infection (3). The adjusted incidence rate for Kaposi's sarcoma decreased from 15.2 per 1000 person-years from 1992 through 1996 to 4.9 per 1000 person-years from 1997 through 1999 in developed countries because of the administration of highly active antiretrovi-ral therapy (HAART) (25).

Current treatment strategies for Kaposi's sarcoma are not curative. Treatment should be individualized based on the extent and rate of tumor growth, tumor-related symptoms, immune system condition, social and cosmetic needs of the patient, and the presence of other HIV-associated illnesses. Treatment options include both local and systemic therapies. Local therapies include surgical excision, laser therapy, cryotherapy, radiotherapy, and intralesion injections. Systemic therapies include HAART, immune-response modifiers, and chemotherapy. HGFs have been used in combination with several systemic therapies including the immune-response modifier interferon-a (IFN-a) and numerous chemotherapy regimens.

0 0

Post a comment